A Phase II study of Rituxmab for the treatment of Sjogrens Syndrome

This study is testing whether a medication called rituximab (Rituxan) can help treat Sjogren's syndrome. Sjogren's syndrome is an autoimmune condition where the immune system attacks moisture-producing glands, causing severe dry eyes and dry mouth. Rituximab works by reducing a certain type of immune cell. Researchers hope it may reduce symptoms and improve saliva and tear production. You may be eligible if: - You are a female - You have been diagnosed with Sjogren's syndrome according to established European-American criteria - Your condition has been stable for at least 3 months - You are not taking aspirin or anti-inflammatory drugs (NSAIDs) within 7 days of biopsies - You are 18 years of age or older You may NOT be eligible if: - Your dry mouth was caused by radiation treatment - You have had previous salivary gland surgery - You have a blocked salivary duct - You are taking certain medications that affect saliva production - You have previously received rituximab - You have had a live vaccine within 4 weeks of treatment - You have a history of cancer, recurring infections, or immune deficiency - You are pregnant or breastfeeding Talk to your doctor about whether this trial might be right for you.